A review of PARP inhibitors: from bench to bedside — Ann Oncol Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, July 20, 2010

A review of PARP inhibitors: from bench to bedside — Ann Oncol



Conclusion: PARP inhibitors show promise as a powerful therapeutic tool, especially in the management of BRCA-associated breast and ovarian cancers but also in tumours where BRCA genes may be dysfunctional. Clinical studies are ongoing and many translational questions remain unanswered that will help clarify how to determine the best way to use PARP inhibitors.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.